Tin tức & Cập nhật

Tarlatamab was associated with significant improvements in overall survival (OS), progression-free survival (PFS) and patient-reported outcomes (PROs) vs standard-of-care (SoC) chemotherapy in patients with small-cell lung cancer (SCLC) undergoing second-line (2L) therapy, according to the primary analysis of the phase III DeLLphi-304 study presented at ASCO 2025.

Nearly one in five hepatitis C virus (HCV) infections in the last decade have been treated with direct-acting antivirals (DAAs), as well as about a third of the target population, according to a study.